Grapiprant and Eribulin for the Treatment of Metastatic Inflammatory Breast Cancer

Summary

This phase Ib/II trial tests the safety and side effects of grapiprant and eribulin and whether they work to shrink tumors in patients with inflammatory breast cancer that has spread to other places in the body (metastatic). Grapiprant is an anti-inflammatory drug that may prevent tumor growth. Eribulin may block tumor cell growth by stopping tumor cell division. Giving grapiprant and eribulin together may help to control the disease.

Timeline

Start

2021-12-21

Primary completion

2024-09-06

Completion

2024-09-06

Drugs

Indications